Applying number-needed-to-treat (NNT) analysis to ophthalmic clinical trials

Optometry and Vision Science

Volumn 83, Issue 12, 2006, Pages 919-930

  Varner, Paul ^a  

^a KELLER ARMY COMMUNITY HOSPITAL   (United States)

Author keywords

Controlled trials; Evidence based medicine; Natural course of the disease; Number needed to treat; Ophthalmic clinical trials; Randomized; Treatment effect

Indexed keywords

BIOMEDICAL ENGINEERING; DISEASES; PATIENT TREATMENT;

CONTROLLED TRIALS; EVIDENCE-BASED MEDICINE; NATURAL COURSE OF THE DISEASE; OPHTHALMIC CLINICAL TRIALS; TREATMENT EFFECT;

OPHTHALMOLOGY;

CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE COURSE; EYE DISEASE; HUMAN; LASER COAGULATION; MEDICAL LITERATURE; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; THERAPY EFFECT; VISUAL IMPAIRMENT;

EVIDENCE-BASED MEDICINE; EYE DISEASES; HUMANS; OPHTHALMOLOGY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 33845774258     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.opx.0000249979.36298.40     Document Type: Review

References (90)

1. Robinson K, Marks H, Goodman S. What we don't know about evidence and medical practice: issues raised by Project ImpACT and lessons from the impact literature The Cochrane Collaboration web site, 2004. Available at: www.cochrane.org/colloquia/abstracts/ottawa/O-039.htm. Accessed January 27, 2006.
2. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ 1997;315:617-9.
3. Berwick DM. Broadening the view of evidence-based medicine. Qual Saf Health Care 2005;14:315-6.
4. Akobeng AK. Principles of evidence based medicine. Arch Dis Child 2005;90:837-40.
5. Bluhm R. From hierarchy to network: a richer view of evidence for evidence-based medicine. Perspect Biol Med 2005;48:535-47.
6. Margolis DJ. Evidence-based dermatology. Cutis 2005;75:8-12.
7. Miller FG, Brody H. Viewpoint: professional integrity in industry-sponsored clinical trials. Acad Med 2005;80:899-904.
8. Urschel JD. How to analyze an article. World J Surg 2005;29:557-60.
9. Kulkarni AV. The challenges of evidence-based medicine: a philosophical perspective. Med Health Care Philos 2005;8:255-60.
10. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative meta-analyses. Proceedings of the National Academy of Sciences of the United States of America web site, January 2001. Available at: www.pubmedcentral.nih.gov/articlerender.fcgi?tool= pubmed&pubmedid=11158556. Accessed January 27, 2006.
11. Cruess AF, Ballantyne M. Clinical trials: where do we go from here? Can J Ophthalmol 1992;27:3-5.
12. Levin LA, Gottlieb JL, Beck RW, Albert DM, Liesegang TJ, Hoyt CS, Dick A, Bhisitkul R, Schachat AP. Registration of clinical trials. Arch Ophthalmol 2005;123:1263-4.
13. Zadnik K. Critically reviewing the ophthalmic literature. Optom Vis Sci 1994;71:254-8.
14. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995;48:45-57.
15. Hatch SW. Ophthalmic Research and Epidemiology: Evaluation and Application. Boston: Butterworth-Heinemann; 1998.
16. Brownson RC. Evidence-Based Public Health. Oxford: Oxford University Press; 2003.
17. Tsay MY, Yang YH. Bibliometric analysis of the literature of randomized controlled trials. J Med Libr Assoc 2005;93:450-8.
18. Sanchez-Thorin JC, Cortes MC, Montenegro M, Villate N. The quality of reporting of randomized clinical trials published in Ophthalmology. Ophthalmology 2001;108:410-5.
19. Singh K. The randomized clinical trial: beware of limitations. J Glaucoma 2004;13:87-9.
20. Van Buskirk EM. Evolution of glaucoma care - from lore to data. Ophthalmology 1997;104:1371-2.
21. Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995;102:1504-8.
22. Newcomb RD, Marshall EC, Public Health and Community Optometry. Boston: Butterworths; 1990.
23. Coleman AL, Singh K, Wilson R, Cioffi GA, Friedman DS, Weinreb RN. Applying an evidence-based approach to the management of patients with ocular hypertension: evaluating and synthesizing published evidence. Am J Ophthalmol 2004;138:S3-10.
24. Abeni D, Girardelli CR, Masini C, Aprea R, Melchi CF, Puddu P, Pasquini P. What proportion of dermatological patients receive evidence-based treatment? Arch Dermatol 2001;137:771-6.
25. Lewis H. Peripheral retinal degenerations and the risk of retinal detachment. Am J Ophthalmol 2003;136:155-60.
26. Hart C. The mysterious placebo effect. Modern Drug Discovery 1999;2:30-40. Available at: www.pubs.acs.org/hotartcl/mdd/99/aug/mysterious. html. Accessed September 12, 2006.
27. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004;256:91-100.
28. Beecher HK. The powerful placebo. JAMA 1955;159:1602-6.
29. Wampold BE, Minami T, Tierney SC, Baskin TW, Bhati KS. The placebo is powerful: estimating placebo effect in medicine and psychotherapy from randomized clinical trials. J Clin Psychol 2005;61:835-54.
30. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609-14.
31. Thomas R, Muliyil J, Paul P. Knowledge of epidemiology and statistics for an ophthalmic practitioner. J Indian Med Assoc 2001;99:561-4, 6.
32. Thomas R, Kumar RS, Chandrasekhar G, Parikh R. Applying the recent clinical trials on primary open angle glaucoma: the developing world perspective. J Glaucoma 2005;14:324-7.
33. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
34. Bussiere M, Wiebe S. The numbers needed to treat for neurological disorders. Can J Neurol Sci 2005;32:440-9.
35. Calculating NNTs. Bandolier web site, February 1997. Available at: www.jr2.ox.ac.uk/bandolier/band36/b36-2.html#calculating. Accessed January 27, 2006.
36. Bradley EA, Bradley D, Bartley GB. Evaluating health-related quality of life in ophthalmic disease: practical considerations. Arch Ophthalmol 2006;124:121-2.
37. Ederer F, Gaasterland DA, Dally LG, Kim J, VanVeldhuisen PC, Blackwell B, Prum B, Shafranov G, Allen RC, Beck A. The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111:651-64.
38. The Age-Related Eye Disease Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119:1439-52. (AREDS-AMD).
39. The Age-Related Eye Disease Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36. (AREDS-C/VL).
40. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82. (BVOS-ME).
41. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 1986;104:34-41. (BVOS-NV)
42. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434-44. (CVOS).
43. Bell TA, Grayston JT, Krohn MA, Kronmal RA. The Eye Prophylaxis Study Group. Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Pediatrics 1993;92:755-60. (CTEPN).
44. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53. (CIGTS).
45. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97. (CNTGS).
46. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998;125:779-96. (COMS-LCM).
47. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119:969-82. (COMS-MCM).
48. Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001;132:463-71.
49. Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci 2003;44:1492-500. (COMET).
50. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001;119:1110-8. (CRYO-ROP).
51. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. (DCCT).
52. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583-600.
53. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108:958-64. (DRVS).
54. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79. (EMGT).
55. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85.
56. Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder AR. Lack of efficacy of light reduction in preventing retinopathy of prematurity. Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. N Engl J Med 1998;338:1572-6. (LIGHT-ROP).
57. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol 1995;113:1479-96. (EVS).
58. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9. (EDIC).
59. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75.
60. Scheiman MM, Hertle RW, Beck RW, Edwards AR, Birch E, Cotter SA, Crouch ER Cruz OA, Davitt BV, Donahue S, Holmes JM, Lyon DW, Repka MX, Sala NA, Silbert DI, Suh DW, Tamkins SM. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005;123:437-47. (ETA).
61. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996;121:349-66. (FFSS).
62. Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9. (GISCR).
63. Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Barron BA, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA, For the Herpetic Eye Disease Study Group. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994;101:1883-95. (HEDS-SKN).
64. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Wilhelmus KR, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA, For the Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 1994;101:1871-82. (HEDS-SKS).
65. The Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. Arch Ophthalmol 1996;114:1065-72. (HEDS-IRT).
66. The Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. Arch Ophthalmol 1997;115:703-12. (HEDS-EKT).
67. The Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998;339:300-6. (HEDS-APT).
68. The Ischemic Optic Neuropathy Decompression Trial Research Group. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000;118:793-8. (IONT).
69. The Krypton Argon Regression Neovascularization Study Research Group. Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization. The Krypton Argon Regression Neovascularization Study report number 1. Ophthalmology 1993;100:1655-64. (KARNS).
70. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13. (OHTS).
71. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 1993;111:773-5. (ONTT).
72. Repka MX, Connett JE, Scott WE. The one-year surgical outcome after prism adaptation for the management of acquired esotropia. Ophthalmology 1996;103:922-8. (PAS).
73. Repka MX, Cotter SA, Beck RW, Kraker RT, Birch EE, Everett DF, Hertle RW, Holmes JM, Quinn GE, Sala NA, Scheiman MM, Stager DR Sr, Wallace DK. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004;111:2076-85. (Atropine).
74. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004;122:1297-305. (RP).
75. Seddon JM, Christen WG, Manson JE, LaMotte FS, Glynn RJ, Buring JE, Hennekens CH. The use of vitamin supplements and the risk of cataract among US male physicians. Am J Public Health 1994;84:788-92. (ASA-Cataract).
76. Berson EL, Rosner B, Sandberg MA, Hayes KC, Nicholson BW, Weigel-DiFranco C, Willett W. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72. (Vit RP).
77. Abrams GW, Azen SP, McCuen BW Flynn HW Jr, Lai MY, Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol 1997;115:335-44. (SS).
78. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234-44. (SRT).
79. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996;114:23-33. (SOCA-CRRT).
80. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61. (SOCA-FGCRT).
81. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med 1997;126:264-74. (SOCA-HPCRT).
82. Hawkins BS, Bressler NM, Bressler SB, Davidorf FH, Hoskins JC, Marsh MJ, Miskala PH, Redford M, Sternberg P Jr, Thomas MA, Toth CA. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. Arch Ophthalmol 2004;122:1597-611.
83. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOPROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000;105:295-310. (STOP-ROP).
84. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207. (TAP).
85. Fulk GW, Cyert LA, Parker DE. A randomized trial of the effect of single-vision vs bifocal lenses on myopia progression in children with esophoria. Optom Vis Sci 2000;77:395-401. (Myopia/EP).
86. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
87. Gragoudas ES, Adamis AP, Cunningham ET Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16. (VEGF).
88. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003;110:667-73.
89. Chalmers I, Matthews R. What are the implications of optimism bias in clinical research? Lancet 2006;367:449-50.
90. Knight J. Negative results: null and void. Nature 2003;422:554-5.